“No Plan” Isn’t “No Risk”: Suicide & Homicide Risk Assessment Lessons from the Clancy Case

 

RISK ASSESSMENT  ·  MEDICATION SAFETY  ·  PROFESSIONAL PRACTICE

“No Plan” Isn’t “No Risk”: Suicide & Homicide Risk Assessment Lessons from the Clancy Case

A companion piece to my earlier post — this one goes deeper on mixed states, the SSRI black box warning, structured risk assessment, and a practice-management lesson about your own professional bio.

My first post on the Lindsay Clancy trial covered the treatment timeline, care fragmentation, and the DSM-5-TR diagnostic gaps around postpartum psychosis. As testimony has continued, several more specific clinical issues have come up that deserve their own discussion: how a mixed bipolar state actually differs from standard postpartum depression, what the FDA's black box warning on antidepressants really covers, how suicidal and homicidal ideation should be assessed structurally rather than as a single yes/no question, and a practice-management lesson that has nothing to do with prescribing at all.

As before: this is an active criminal trial, and Clancy has also filed a malpractice suit against several of her treating clinicians, while her ex-husband has filed a separate wrongful death suit. The complaints contain allegations that have not been adjudicated, and the defendants have not been found liable for anything. Nothing here is a comment on the outcome of that litigation — it's a look at the general clinical and professional-practice principles the testimony happens to illustrate.

⚠ Before We Go Further This post discusses suicidal and homicidal ideation assessment in clinical detail, for a professional audience of NP students and new graduates. If you are personally struggling with thoughts of suicide or harming yourself or others, please reach out for support — the 988 Suicide & Crisis Lifeline (call or text 988) is available 24/7 in the U.S.

1. What a Mixed Bipolar State Actually Looks Like — and Why It's Easy to Miss

Testimony has described Jollotta's initial working diagnosis as postpartum depression and anxiety. She raised an underlying bipolar disorder or mixed manic/hypomanic state as a differential consideration after Clancy described going roughly 48 hours without sleep following a reaction to Zoloft, and she testified she disclosed this concern to Clancy and her husband directly, in person, on December 6th — Patrick responded, “my wife is not bipolar”; Lindsay said nothing. Worth noting precisely, since it changes the lesson: a structured screen (the Mood Disorder Questionnaire, administered earlier by a colleague) had come back negative — Clancy endorsed only 3 of the 13 listed symptoms, well under the threshold for a positive screen. Jollotta testified she stayed concerned anyway, citing the MDQ's known lower sensitivity for bipolar II and NOS presentations, and continued to act on the differential afterward: holding Prozac and titrating Seroquel on the FDA's mania-dosing schedule rather than the depression-dosing schedule, over the family's stated skepticism.

In uncomplicated postpartum depression, sleep disturbance is congruent with the depressive picture: the patient is exhausted, whether or not she's actually sleeping. A mixed state looks different. DSM-5-TR defines a mixed features specifier as a major depressive (or manic/hypomanic) episode with at least three symptoms from the opposite pole present concurrently. The hallmark most relevant here is a dramatically reduced need for sleep that is not accompanied by fatigue — the patient may describe feeling wired, restless, or flooded with emotion rather than depleted, even after 48 hours awake.

The teaching point this transcript actually supports is more specific than “watch for this symptom”: a negative structured screen doesn't close the question when the tool's own sensitivity is known to be lower for the exact subtype in play. Documenting that reasoning — why you're staying concerned despite a negative screen, and what you did about it — is what turns a clinical hunch into a defensible clinical judgment. It's also worth naming plainly: disclosing a bipolar concern to a patient and her spouse, and having them push back on it, doesn't obligate a clinician to drop the differential, and this transcript shows Jollotta didn't — she kept adjusting the medication plan around it even as the family disagreed.

Other features worth actively screening for alongside sleep changes: racing thoughts, pressured speech, psychomotor agitation, irritability, and increased impulsivity or risk-taking. That combination — depressive hopelessness plus manic-spectrum energy and impulsivity — is considered one of the highest-risk presentations in psychiatry, because it can pair the motivation to act with the activation to act on it. This is precisely why a single atypical reaction to an antidepressant, especially one involving profound sleep loss without fatigue, deserves a structured bipolar screen (the Mood Disorder Questionnaire is a quick, validated option) rather than being folded into the existing PPD diagnosis and treated with reassurance or another sedative.

2. The FDA Black Box Warning: What It Actually Covers

The FDA's black box warning on antidepressants, in place since 2004 and updated since, is often summarized loosely as “SSRIs can cause suicidal thoughts,” which undersells what it's actually about. The warning specifically addresses increased risk of suicidal thinking and behavior in children, adolescents, and young adults up to age 24 who are started on an antidepressant, concentrated in the first one to two months of treatment or shortly after a dose change.

The mechanism the warning is built around is essentially activation syndrome: agitation, akathisia-like restlessness, insomnia, irritability, hostility, and impulsivity emerging early in treatment — sometimes before mood has actually improved. That creates a specific high-risk window where a patient has more energy and activation but is still deeply depressed, which is a materially different risk profile than either symptom alone.

Two points worth being precise about for practice: first, even outside the FDA's specific age cutoff, the underlying principle — that early antidepressant treatment can transiently increase agitation and risk before benefit appears — is considered clinically relevant across ages and should be part of informed consent and early monitoring for any patient starting or changing an SSRI/SNRI, postpartum patients very much included. Second, the warning is a reason for closer follow-up in the first weeks of treatment — checking in within days, not weeks — not a reason to avoid antidepressants altogether in patients who need them.

3. Structured Risk Assessment: Why “No Plan” Isn't the End of the Conversation

This is arguably the most practically important section for day-to-day charting. “Denies plan” is one of the most common phrases in psychiatric documentation — and one of the most commonly over-relied-upon. Absence of a stated plan is one input into a risk assessment, not a stand-alone reassurance that closes the inquiry.

Structured tools like the Columbia-Suicide Severity Rating Scale (C-SSRS) treat ideation, intent, plan, means, and history of attempts as separate dimensions that each need to be asked about and documented individually. A patient can have passive or even active ideation with no articulated plan and still carry meaningfully elevated risk, particularly when other risk factors are stacking up — sleep deprivation, mixed-state features, a recent hospitalization, access to lethal means, and the postpartum period itself, which independently elevates risk.

In the postpartum context specifically, risk assessment has a second, distinct track that has to be asked about directly rather than inferred from a mood screen: thoughts of harm toward the infant. These thoughts occur on a real spectrum. On one end, intrusive, unwanted, ego-dystonic thoughts of harm are extremely common in postpartum anxiety and postpartum OCD — the patient finds them horrifying and would never act on them, and simply having them is not, by itself, a sign of psychosis. On the other end, thoughts that feel ego-syntonic, commanding, or paired with a plan or intent are a psychiatric emergency. Distinguishing between those two ends requires direct, explicit questioning: What is the content of the thought? Is it distressing and unwanted, or does it feel right or necessary? Is there intent? Access to the infant? Who else is supervising or available? A generic “denies harming baby” note doesn't capture where on that spectrum a patient actually sits.

The documentation lesson: a defensible risk note documents ideation, intent, plan, means, protective factors, and the clinician's stated reasoning for the risk level assigned — not just the single data point of “no plan.” When a chart shows only “denies plan” with nothing else, that tends to read, in hindsight, as a superficial screen rather than a clinically reasoned risk assessment, regardless of how much thought actually went into it at the time. Write down the reasoning, not just the conclusion.

Worth noting: Jollotta's own testimony describes documentation more granular than a bare “denied” — she testified to repeatedly asking about plan and intent specifically, documenting “SI, no plan, no intent” at multiple points in December, and asking directly whether Clancy had any thoughts of harming her children, which Clancy denied every time she was asked. That's closer to the defensible end of the spectrum than the thin end. The general principle still stands — plan-only documentation is a common and real failure mode worth guarding against — but on the primary record here, this particular case shows a more structured line of questioning than “denies plan” alone.

✓ Clinical Bottom Line •     Severe insomnia without accompanying fatigue after starting or increasing an antidepressant is a red flag for a mixed or manic state, not just “bad sleep” — screen formally rather than treating it as a side effect to wait out. •     The SSRI black box warning is about early-treatment activation syndrome creating a window of increased energy paired with persistent depression — it's a cue for closer follow-up in the first weeks, not a reason to avoid treatment. •     “Denies plan” is one data point in a multi-dimensional risk assessment (ideation, intent, plan, means, protective factors) — never document it as the whole assessment. •     Postpartum harm-related intrusive thoughts require their own direct line of questioning, separate from a general mood or suicide screen — content, distress level, intent, access, and supervision all need to be asked about explicitly. •     Document your risk-level reasoning, not just your risk-level conclusion — the “why” is what makes a risk assessment defensible later.

4. A Lesson That Has Nothing to Do With Prescribing: Your Own Bio

One exchange from testimony is worth pulling out separately because it's not a clinical issue at all — it's a practice-management one. On cross-examination, testimony indicates Jollotta was confronted with website language describing her as having expertise in postpartum depression and postpartum psychosis; she characterized her actual background as more of a personal clinical interest, and said she was not aware of the specific language on her website. We're not going to speculate here about how that exchange affects the litigation — that's a legal judgment for the attorneys and experts actually involved in the case, not something to analyze from the outside.

What is worth taking from it, as a general practice principle: your public-facing professional bio — on a practice website, a hospital system page, a directory listing, LinkedIn — is a document that can be read back to you, and holding yourself out (even unintentionally, even via a marketing vendor's language you never reviewed) as having expertise in a specific condition can raise the standard you're compared against if something goes wrong with a patient who has that condition.

•     Review your own bio, on every site it appears, at least annually — don't assume a practice manager, marketing vendor, or hospital system got the language right, and don't assume it stays accurate once written.

•     Be precise about the difference between clinical interest, additional continuing education, formal certification, and specialization — these terms aren't interchangeable, and “expert” or “specialist” language implies a level of credentialing that most general FNPs or PMHNPs, even ones who see a lot of a given patient population, don't formally hold without specific fellowship training or certification.

•     If your practice's marketing overstates your scope, get it corrected. This isn't only about litigation exposure — a mismatch between what your bio promises and what you're actually positioned to manage can set patients up with the wrong expectations from the first visit, which is a patient-safety issue in its own right.

◆ A Nuance Worth Sitting With It's tempting to read the mixed-state and black-box-warning content above and conclude every postpartum patient with insomnia after starting an SSRI needs an urgent bipolar workup. That's not the right takeaway, and treating it that way would flood an already-thin perinatal psychiatric referral system with low-yield urgent evaluations. The skill being asked for here is specificity: it's the combination of features — reduced sleep need without fatigue, plus racing thoughts or agitation, plus a symptom trajectory that's getting worse rather than better on treatment — that should raise concern, not any single symptom in isolation. Most patients who report trouble sleeping on a new antidepressant are having ordinary insomnia, not a mixed episode.

Is Writing “Denied” Enough? A Closer Look at Outpatient Documentation

This deserves its own section because it's one of the most common documentation habits in outpatient behavioral health, and one of the thinnest. “Denied SI/HI” by itself tells a reviewer that you asked something and got a negative answer — it doesn't show what you actually asked, whether you assessed passive versus active ideation separately, whether known risk factors were weighed, or why you landed on the disposition you chose. In a chart review, a peer audit, or a hindsight analysis after a bad outcome, a bare “denied” tends to read as a box that was clicked, not a clinical judgment that was made.

A more defensible outpatient note includes several distinct elements, not just a global conclusion:

•     The screening method itself — name the tool used (e.g., C-SSRS, PHQ-9 item 9) or the actual questions asked, rather than only the result.

•     Ideation, intent, plan, means, and history documented as separate dimensions — passive versus active ideation in particular, since they carry different risk weight.

•     Homicidal/infant-harm ideation asked about and documented on its own line, distinct from the general SI screen — and, when thoughts are present, whether they are distressing/unwanted (anxiety-spectrum, lower acute concern) or ego-syntonic/commanding (higher concern), plus intent, access, and available supervision.

•     Protective factors named explicitly — support system, insight, future orientation, treatment engagement — rather than left for the reader to infer.

•     The clinician's actual reasoning and disposition, in a sentence — what risk level was assigned, why, and what happens next (follow-up interval, safety plan, crisis resources provided).

•     Context from that specific visit — recent medication changes, sleep status, symptom trend since the last encounter — so the note reflects this visit rather than reading as identical boilerplate every time.

A quick before-and-after illustrates the gap. Thin: “Denies SI/HI.” Defensible: “Denies active suicidal ideation, plan, or intent; endorses occasional passive thoughts of wanting to sleep and not wake up, present intermittently over the past 2 weeks, no worsening. No history of attempts. Directly asked about thoughts of harming infant — denies any such thoughts, including intrusive/unwanted ones. Protective factors: engaged in care, supportive spouse in home, future-oriented regarding children. Risk assessed as low at this time. Safety plan and crisis resources reviewed; follow-up in 1 week or sooner if symptoms escalate.” The second version takes perhaps 45 extra seconds to write. That's the difference between a note that demonstrates clinical judgment and one that only demonstrates a question was asked.

Quick Reference: Documentation Checklist

•     Risk assessment includes ideation, intent, plan, means, protective factors, and stated clinical reasoning — not just a plan status.

•     Harm-related intrusive thoughts (postpartum) are screened with direct questions about content, distress level, intent, access, and supervision — documented separately from a general SI screen.

•     Any new or worsening agitation, insomnia, or activation within weeks of starting/changing an antidepressant is documented with a follow-up interval, not just a reassurance note.

•     An atypical reaction to an antidepressant (e.g., severe insomnia without fatigue) is documented as a differential-diagnosis trigger, with the screening tool used (or the reasoning for not using one) noted explicitly.

•     Your own professional bio and marketing language are reviewed periodically and kept consistent with your actual training, certification, and scope.

•     SI/HI screening notes name the method used and document ideation, intent, plan, means, and protective factors as separate elements — never “denied” alone.

The Defense's Core Critique: Why “Checklist-Style” Care Is a Structural Question, Not Just an Individual One

Clancy's defense has argued more broadly that her medical team relied too heavily on brief, checklist-style assessments and failed to recognize the underlying severity of what the defense characterizes as postpartum psychosis and adverse medication reactions. It's worth closing on this critique directly, because it isn't really an argument that one symptom got missed — it's an argument that the format of care itself is structurally mismatched to catching a condition that is rare, fast-moving, and doesn't present in a checklist-friendly way. That's a useful lesson independent of how the litigation resolves.

•     A checklist can confirm a diagnosis; it can't rule one out. Tools like the EPDS, PHQ-9, or a structured SI screen are validated for detecting the condition they're built to detect — not a rarer, faster-moving condition hiding underneath a more common one. A reassuring score answers a narrow question (“does this look like standard PPD today”) and should never be read as answering the broader one (“is something more serious developing”).

•     Brevity is the enemy of trajectory. A single well-conducted visit is a snapshot; postpartum psychosis and mixed bipolar states are defined by their trajectory — worsening despite treatment, atypical reactions, symptoms that don't fit the working diagnosis. That trajectory is only visible by deliberately comparing this visit to the last several, not by any one screen administered fresh each time.

•     Checklists measure symptoms; they don't measure treatment-resistance or paradoxical worsening. A pattern of repeated medication changes without improvement — or reactions that make things worse rather than better — is often a stronger signal than any single symptom score, but it lives in longitudinal clinical judgment, not in a tool's output, and has to be actively tracked and documented as its own finding.

•     Standardized tools are a floor, not a ceiling. They ensure a baseline set of questions gets asked reliably, especially in time-pressured primary care or telehealth settings — they are not a substitute for clinical judgment once a presentation stops fitting the pattern the tool was validated on. Atypical insomnia, medication reactions moving the wrong direction, or escalating contact frequency are all cues to lean on judgment and consultation rather than the next scheduled screen.

•     “Checklist-style” care is often a symptom of system design, not individual failure. Short visit windows, high caseloads, and portal-message triage are structural features of how much behavioral health is delivered, particularly in perinatal programs stretched thin on specialist capacity. The more durable fix isn't asking individual clinicians to be more vigilant in a 15-minute visit — it's building structural safeguards: mandatory trajectory review at defined intervals, low-threshold psychiatric consult triggers, and explicit criteria for escalating a patient out of brief-visit format.

The one-line version worth remembering: a validated screening tool tells you what's present today; it can't tell you what's building underneath. Treating a reassuring score as closure, rather than as one data point in an ongoing trajectory, is where checklist-style care stops being a safeguard and starts being a liability.

One caveat worth stating plainly: Jollotta's own testimony describes something more active than a single static checklist applied on repeat. She tracked Clancy's Edinburgh and GAD-7 scores visit to visit, adjusted her differential as the trajectory changed, disclosed a bipolar concern to the family, and titrated medication against a bipolar-specific dosing schedule rather than the depression schedule once she suspected a mixed state. Whatever the jury ultimately concludes about the adequacy of that response, the record doesn't show a clinician mechanically re-running the same screen and calling it done — it shows ongoing clinical judgment operating alongside the screens. The structural critique above is worth taking seriously as a general principle for how perinatal psychiatric care is often delivered; it's a separate question from whether it's a fully accurate description of this specific clinician's actual process, and the primary testimony suggests the latter is more nuanced than the checklist framing implies.

References

MDLinx. “Lindsay Clancy’s malpractice suits put postpartum psychiatric care under a microscope.” July 30, 2026.

U.S. Food and Drug Administration. Antidepressant Use in Children, Adolescents, and Adults — boxed warning information. Updated guidance.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). 2022.

Columbia Lighthouse Project. Columbia-Suicide Severity Rating Scale (C-SSRS).

American College of Obstetricians and Gynecologists (ACOG). Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum, Clinical Practice Guideline. 2023.

Commonwealth v. Lindsay Clancy. Plymouth Superior Court trial testimony of Rebecca Jollotta, CNP, and related proceedings, August 2026.

This post is for clinical education purposes only and does not constitute legal commentary, medical advice, or a judgment of any individual involved in ongoing litigation. Case facts are drawn from public court reporting and may evolve as the trial continues.

When the Chart Isn't Enough: What NP Students Can Learn from the Lindsay Clancy Case

 

CASE-BASED LEARNING  ·  MENTAL HEALTH  ·  RISK MANAGEMENT

When the Chart Isn't Enough: What NP Students Can Learn from the Lindsay Clancy Case

A trial making national headlines is also, quietly, a case study every psychiatric-mental-health and primary care NP student should sit with.

In August 2026, testimony resumed in the Massachusetts murder trial of Lindsay Clancy, the Duxbury mother charged with killing her three children — Cora, 5; Dawson, 3; and Callan, 8 months — in January 2023. Clancy has pleaded not guilty. Her defense argues she was in the grip of postpartum psychosis and an underlying bipolar disorder that went unrecognized; prosecutors argue she acted intentionally and rationally. That legal question is for the jury, and nothing here takes a position on it.

What is useful for us, as clinicians who write prescriptions and answer portal messages between visits, is the clinical picture that has emerged from testimony: two nurse practitioners, a psychiatrist, telehealth visits, portal messages arriving nearly every day, and a patient moving between at least three different care systems that never fully talked to each other. Whatever the jury ultimately decides about intent, the treatment timeline itself is a case study in how postpartum mood and anxiety symptoms can be managed by the book and still go sideways — and where the seams in our systems tend to be.

⚠ Before We Go Further This is an active criminal trial and a pending civil suit against several of the treating clinicians, who have denied the allegations against them. Details below are drawn from court testimony reported by major outlets and are presented for clinical education only — not as a verdict on anyone's care, competence, or intent. Treat every clinician in this story the way you'd want to be treated if your own worst week of charting were read back in a courtroom.

The Timeline, As It Has Been Described in Testimony

Clancy's psychiatric care began in September 2022, a few months after her third child was born, when she was started on treatment by psychiatrist Dr. Jennifer Tufts, who saw her by telehealth 14 times over the following four months and wrote roughly half of her approximately 30 total psychiatric prescriptions. In late November 2022, an NP colleague transferred Clancy's case to Rebecca Jollotta, a psychiatric nurse practitioner with a hospital's perinatal behavioral health program, who built a treatment plan targeting anxiety, depression, and insomnia.

From there, testimony describes a pattern many of us will recognize: near-daily portal messages. Clancy reported intrusive thoughts, worsening insomnia, and a frightening sense of numbness — writing at one point that she felt she was "going to die" and didn't care. She repeatedly asked to change medications, often stopped taking a new prescription before it had time to work, and voiced fear of becoming dependent on the benzodiazepines she'd been given for sleep. Jollotta's working diagnosis was postpartum depression and anxiety, but she testified she raised an underlying bipolar disorder as a differential as early as her first visit, based on Clancy's atypical, non-fatigued response to Zoloft — and disclosed that concern directly to Clancy and her husband on December 6th. A structured screen (the Mood Disorder Questionnaire, administered by the prior NP) had come back negative, but Jollotta testified the tool is less sensitive for bipolar II or unspecified bipolar presentations, and continued to act on the differential afterward: holding Prozac and titrating Seroquel on the FDA's manic-episode dosing schedule rather than its depression schedule, even after Clancy's husband pushed back, saying, "My wife is not bipolar."

Jollotta testified she directly and repeatedly assessed suicidal ideation, asking about plan and intent at multiple points in December and documenting "SI, no plan, no intent" each time, including on a joint call with Clancy's husband. She also recommended escalation to a higher level of care more than once — a partial hospitalization program at an out-of-state hospital in mid-December, and inpatient options (including the mechanics of ED-to-inpatient bed access) discussed explicitly in a December 15th call. In late December, Clancy was evaluated at that out-of-state hospital's day program, which recommended tapering her off one antipsychotic; on New Year's Eve she was admitted to a psychiatric facility for inpatient stabilization and was later discharged with an outpatient follow-up plan. Jollotta testified she never obtained records from either institution — she did not request them, and disputes the out-of-state hospital's record indicating they called her office and got no response, saying she never received such a call. She did not prescribe anything further in January. The children were killed on January 24, 2023, after which prosecutors say Clancy took some of her own medication, cut herself, and fell from a second-floor window. A forensic toxicologist later testified that her blood levels of the antipsychotic quetiapine were roughly ten times below a toxic threshold — testimony the prosecution used to argue that medication was not driving her behavior that day, while the defense countered that a drug level is a poor stand-in for someone's overall clinical state.

What This Case Is Actually Teaching Us

1. A surge in portal messages is data, not just workload

Nearly-daily messages reporting worsening symptoms, requests to change medication, and statements like feeling "numb" and wanting to "die" are not noise to triage between patients — they are an escalating clinical picture arriving one inbox message at a time. It's easy, especially in a high-volume portal, to answer each message as its own small problem (reassure, adjust, encourage patience) without stepping back to ask what the trend line looks like. Build a habit of pattern-recognition: if you've responded to the same patient three or four times in two weeks, that's a signal to escalate the encounter type — a same-day visit, a check-in call, a safety screen — rather than another message reply.

2. Nonadherence doesn't mean the risk has gone away

Clancy reportedly often stopped medications early or took less than prescribed, out of fear of side effects and benzodiazepine dependence. That's a completely understandable patient response — and also one that muddies the clinical picture, because a nonadherent patient can look "undertreated" on paper while still carrying real, escalating risk. When a patient tells you they're not taking something as prescribed, that disclosure is worth more than a note in the chart; it's an opening to ask directly what's driving the fear, and to revisit the plan together rather than simply restating it.

3. Treatment-resistant insomnia and depersonalization deserve a harder look, not just reassurance

Being told a medication "takes several weeks to work" is accurate and often the right thing to say — until the symptom in question is severe, refractory insomnia or a patient describing feeling emotionally numb and detached. Those two symptoms in particular are worth treating as potential red flags for something beyond straightforward postpartum depression: an evolving mixed or manic state, or early depersonalization that can precede a psychotic break. Sleep deprivation is not just uncomfortable in the postpartum period — it is a recognized, modifiable driver of manic and psychotic episodes, which makes it a vital sign in this population, not a side complaint.

4. A negative structured screen doesn't close the question

The Mood Disorder Questionnaire Clancy was given came back negative — she endorsed only 3 of the 13 listed symptoms, well short of the 7 needed to screen positive. Jollotta testified she knew the MDQ is less sensitive for bipolar II or bipolar-not-otherwise-specified presentations, and kept the differential open anyway, reasoning from the atypical medication reaction itself rather than deferring entirely to the screen. That's the right instinct, and worth naming explicitly: a validated tool's negative result narrows the odds, it doesn't rule the condition out, and a clinician who has a specific reason to distrust a tool's sensitivity for a given presentation is right to keep asking questions the tool didn't ask.

5. Disclosing a differential to the family is necessary, but not sufficient, when they push back

Jollotta told Clancy and her husband directly, in person, that she suspected an underlying bipolar disorder — and continued titrating medication on a bipolar treatment schedule afterward. Her husband responded, "My wife is not bipolar," and Clancy said nothing. That moment is worth sitting with: disclosing a differential is necessary, but a family's discomfort with a diagnosis doesn't mean the clinical plan should quietly soften. To her credit, testimony indicates Jollotta didn't abandon the differential after the pushback — she kept dosing toward it. The harder, less resolved question the case raises is what happens next when a family pushes back on a working diagnosis: how, and how often, to revisit it, and how to keep documentation honest about the disagreement without it reading, in hindsight, as capitulation.

6. Care fragmentation is where risk hides

Across roughly four months, Clancy was seen by a psychiatrist and at least two NPs by telehealth, self-referred to an out-of-state specialty hospital, and completed a psychiatric inpatient stay. Jollotta testified she never obtained records from the psychiatrist, the out-of-state hospital, or the inpatient facility — not because a request was denied, but because she never made one, relying instead on what Clancy reported about each encounter. The out-of-state hospital's own record states they tried to reach her office and got no callback; Jollotta disputes ever receiving that call. Whichever account is accurate, the deeper lesson is the same: when care is split across institutions that don't share a records system, a phone tag or a missed request can sit invisibly for weeks with nobody positioned to notice, and "the patient will tell me what happened" is not a substitute for the discharge summary or a documented records request, sent and followed up on, on your own side of the gap.

7. Lab values and toxicology answer a narrower question than they seem to

The toxicologist's testimony that quetiapine levels were far below a toxic threshold is a good real-world illustration of something worth teaching explicitly: a blood level tells you about drug concentration at one moment, not about a person's overall psychiatric state, especially once psychosis, dissociation, or a manic episode is in play. Don't let a reassuring lab value substitute for a face-to-face mental status exam, and don't assume a low level rules out a medication's contribution to what's unfolding clinically.

Before You Escalate the Medication Regimen: What Baseline Labs Can Rule Out

It's worth separating two very different kinds of lab testing, because they get conflated constantly in both practice and in courtroom testimony. Therapeutic drug monitoring — measuring the blood concentration of a psychiatric medication itself — is genuinely not routine for most antidepressants; it's reserved for narrow-therapeutic-index drugs like lithium and clozapine. But baseline medical labs to rule out organic, treatable mimics of a mood or anxiety presentation are a different question entirely, and are considered standard of care in a thorough initial psychiatric workup — especially postpartum, when several of these conditions are common and their timelines overlap almost exactly with expected postpartum depression or anxiety.

A baseline panel worth considering before you escalate a psychiatric medication regimen:

•     TSH and free T4 (± free T3): postpartum thyroiditis affects an estimated 5–10% of postpartum women and classically runs a transient hyperthyroid phase (anxiety, insomnia, palpitations, irritability) followed by a hypothyroid phase (depression, fatigue, brain fog) — a timeline that overlaps almost perfectly with expected PPD onset.

•     CBC: postpartum anemia from delivery blood loss is common and can present as fatigue, poor concentration, and low mood that gets read as purely psychiatric.

•     Basic metabolic panel/electrolytes and renal function: rules out sodium and other electrolyte disturbances that can cause confusion, agitation, or mood lability.

•     Fasting glucose or HbA1c: persistent gestational diabetes or undiagnosed insulin resistance can drive mood swings, irritability, and cognitive symptoms.

•     Vitamin B12 and folate: deficiency impairs neurotransmitter synthesis and can present as depression, fatigue, and, in severe cases, cognitive or psychotic-like symptoms.

•     Vitamin D: increasingly linked to depressive symptoms; deficiency is common postpartum, especially with limited sun exposure and breastfeeding.

•     Iron studies/ferritin: iron deficiency without frank anemia is linked to fatigue, low mood, and restless sleep.

Why this belongs in the differential: if a patient presents with severe insomnia, anxiety, and mood symptoms and this workup was never done or documented, medication changes are being made without having excluded reversible causes that wouldn't respond to psychiatric treatment at all — meaning a dose could be escalated, or a drug switched, while the actual driver goes unaddressed. A documented baseline workup (or a documented, reasoned decision to skip it) is part of what makes a treatment plan defensible in hindsight, not just clinically sound in the moment.

Psychotherapy as a Modality — Not Just an Afterthought to Medication

One thing worth naming directly in this case: a patient who is telling her clinicians that medications are making her feel worse, not better, is giving a clear signal to lean harder into a non-pharmacologic track — not just to keep rotating agents. Psychotherapy is not appropriate as the sole treatment once a patient is in an acute manic, mixed, or psychotic state, or is expressing intrusive thoughts of harm — safety stabilization comes first, and that often means medication and a higher level of care. But for postpartum depression and anxiety in a patient who is engaged in her own care and not in acute crisis — which describes much of Clancy's early treatment course — psychotherapy is first-line, evidence-based treatment in its own right, not a soft adjunct to be mentioned once and left unaddressed.

•     Cognitive Behavioral Therapy (CBT): strong evidence base specifically for postpartum depression and anxiety; targets catastrophic thinking about the baby's safety and all-or-nothing beliefs about being a “good mother”; structured and time-limited (roughly 8–16 sessions), which fits a population with little time and high fatigue. Also the modality of choice for postpartum anxiety/OCD presentations — intrusive thoughts about harm are common in postpartum anxiety and OCD and are usually not a sign of psychosis, a distinction worth making explicitly since it's one of the most misunderstood areas in perinatal mental health.

•     Interpersonal Therapy (IPT): specifically validated for postpartum depression; targets role transition (the identity shift into motherhood, loss of prior roles) and interpersonal strain (partner conflict, lack of support) — exactly the territory driving much of postpartum distress that medication alone doesn't touch. Many perinatal specialists consider it the best-fitted modality for PPD for this reason.

•     Behavioral activation: a lower-intensity option — structured re-engagement with valued activity and social contact — useful when a patient is too overwhelmed or sleep-deprived for the full cognitive work of CBT, or as a bridge while awaiting therapy access.

•     Group-based perinatal support: peer support groups (clinician-facilitated or otherwise) reduce isolation, itself a major risk amplifier; a valuable adjunct, not a substitute for individual treatment in moderate-to-severe presentations.

A reasonable prescribing sequence this case argues for: confirm baseline labs are done; for mild-to-moderate presentations, offer psychotherapy (CBT or IPT) as first-line with medication as adjunct or second-line if therapy access is delayed; for moderate-to-severe presentations or limited therapy access, run medication and therapy concurrently rather than medication alone with therapy deferred; and if a patient reports medications are worsening rather than helping, treat that as a cue to lean harder into the non-pharmacologic arm and reassess the diagnosis — not simply to try another drug in the same category. Document the therapy referral itself, whether it was accepted, and any access barriers (insurance, waitlist, childcare) — a documented offer of therapy a patient couldn't access reads very differently in hindsight than no mention of therapy at all.

✓ Clinical Bottom Line •     A cluster of near-daily portal messages describing worsening mood, sleep, or intrusive thoughts is an escalation signal — move the patient into a higher-touch encounter, don't just keep answering messages. •     Treatment-resistant insomnia and reports of emotional numbness/depersonalization in the postpartum period warrant explicit screening for mania, psychosis, and bipolar spectrum illness — not just "give it more time." •     Medication nonadherence is a conversation starter, not a data point to file away — ask what's driving it. •     A reassuring toxicology or lab result narrows one question; it doesn't close the broader risk assessment. •     A baseline metabolic/endocrine workup (TSH, CBC, BMP, B12/folate, vitamin D) belongs early in a postpartum mood or anxiety presentation — several organic mimics share the exact same timeline as expected PPD onset. •     A severe (not mild) activation reaction to an SSRI, especially with treatment-resistant insomnia, is a cue to formally screen for bipolar spectrum illness — but know the MDQ's limits: a negative screen doesn't rule out bipolar II or NOS presentations, and a strong clinical suspicion can outweigh a negative structured tool. •     A patient reporting that medication is making things worse, not better, is a cue to intensify the psychotherapy track (CBT/IPT) alongside or instead of another medication change — not just to keep rotating agents. •     When a family pushes back on a disclosed differential diagnosis, that pushback is a cue to document the disagreement and revisit it deliberately — not a cue to quietly let the working diagnosis drop. •     After any ED visit, specialty consult, or inpatient stay, send and follow up on an actual records request on your own side — don't rely on the other institution to call, and don't rely on patient self-report to reconstruct what happened elsewhere. •     Document your clinical reasoning at each medication change, not just the change itself — the "why now" is what protects both the patient and you.

◆ A Nuance Worth Sitting With It would be easy to read this case and conclude the answer is simply "escalate everything, screen for everything, refer everyone." In practice, most patients reporting postpartum insomnia, anxiety, and medication side effects are exactly what they appear to be — and treating every one of them as an impending psychiatric emergency would be its own kind of harm, eroding trust and overwhelming a system that's already short on perinatal psychiatric capacity. The clinical skill this case is really asking us to build isn't more suspicion across the board; it's a sharper eye for the small number of signals — refractory insomnia, depersonalization, a diagnosis that isn't responding the way it should, care split across systems that aren't talking — that mean this particular patient needs more than the standard next step.

Board & Practice Review: Postpartum Mood and Psychotic Disorders

Key distinctions to have cold

•     Postpartum blues: onset within days of delivery, peaks around day 3–5, resolves within two weeks without treatment — no functional impairment beyond mild tearfulness/irritability.

•     Postpartum depression (PPD): onset typically within the first month but can emerge up to a year postpartum; meets criteria for a major depressive episode with peripartum onset per DSM-5-TR; screen with validated tools such as the Edinburgh Postnatal Depression Scale (EPDS).

•     Postpartum psychosis: not a standalone DSM-5-TR code — captured as a specifier/presentation of bipolar disorder, brief psychotic disorder, or (rarely) schizophrenia with peripartum onset; rapid onset, often within the first 2 weeks postpartum; psychiatric emergency requiring immediate evaluation, usually inpatient.

•     Key red flags that should raise suspicion for an evolving bipolar or psychotic process rather than uncomplicated PPD: refractory insomnia despite treatment, rapid mood lability, depersonalization/derealization, disorganized thinking, new-onset paranoia, or any expressed intrusive thoughts of harm.

•     Antidepressant-induced activation syndrome: agitation, akathisia-like restlessness, insomnia, and irritability emerging after starting or increasing an SSRI/SNRI — a signal to pause and reassess for underlying bipolarity before adding or switching within the same drug class.

•     Sleep deprivation is both a symptom and a risk multiplier in postpartum mood disorders — it should be actively treated and tracked, not treated as an expected inconvenience of new parenthood.

DSM-5-TR: the diagnostic detail that actually matters here

It's easy to assume all three of the phenomena above have equally formal diagnostic criteria. They don't — and knowing exactly where each one sits in DSM-5-TR is what separates a clean clinical explanation from a hand-wave.

•     Antidepressant-induced activation syndrome has no DSM-5 code at all. It is a recognized adverse drug reaction described in FDA labeling and the pharmacology literature, not a diagnosable psychiatric disorder — it's identified by temporal association (onset or worsening tied to starting/increasing the drug) and confirmed by improvement on dose reduction or discontinuation, not by a criteria checklist. If akathisia is the dominant feature, DSM-5-TR does have a specific code, Medication-Induced Acute Akathisia, under medication-induced movement disorders — but that covers the motor restlessness alone, not the full activation picture.

•     An SSRI unmasking latent bipolar disorder does have formal DSM-5-TR grounding, and the criteria matter: a manic or hypomanic episode that emerges during antidepressant treatment can be coded as Substance/Medication-Induced Bipolar and Related Disorder — but DSM-5-TR includes a deliberate exclusion clause stating that if the full manic or hypomanic episode persists at a syndromal level beyond the expected physiological effect of the medication, that persistence is itself sufficient evidence for a true Bipolar I or Bipolar II diagnosis, not merely a substance-induced one. In plain terms: DSM-5 explicitly treats a mania that doesn't resolve when the drug's effect should have worn off as evidence the medication revealed a real underlying bipolar disorder, rather than manufactured a temporary one. This is the exact clinical argument behind the “unmasking” theory raised in cases like this.

•     Postpartum psychosis has no standalone DSM-5-TR diagnosis — there is no listed disorder by that name. What exists instead is a “with peripartum onset” specifier, which can attach to a Major Depressive Episode or Manic Episode (with onset in pregnancy or within 4 weeks postpartum, including mood-congruent or mood-incongruent psychotic features), or to Brief Psychotic Disorder (psychotic symptoms lasting 1 day to 1 month with full return to baseline functioning, also with a peripartum-onset specifier).

•     The specifier's 4-week window is a real, clinically debated limitation: the research and clinical literature describe postpartum psychosis emerging anywhere from days to several months postpartum, most commonly in the first two weeks but not confined to a 4-week cutoff. A patient who becomes psychotic at 6 or 8 weeks postpartum doesn't cleanly qualify for the specifier at all, even though it's clinically the same phenomenon — clinicians often end up using Other Specified Bipolar and Related Disorder or Other Specified Schizophrenia Spectrum and Other Psychotic Disorder to code around that gap.

•     In practice, most cases clinically labeled “postpartum psychosis” ultimately resolve to a diagnosis of Bipolar I Disorder, manic or mixed episode, with psychotic features, with peripartum onset — the majority of women who experience it are later found to have bipolar spectrum illness, which is part of why screening for bipolarity (not just depression) in a postpartum patient with severe or atypical symptoms is diagnostically, not just cautiously, indicated.

•     The practical consequence of this diagnostic gap: because there's no standalone code, there's no dedicated, universally adopted screening pathway for postpartum psychosis the way the EPDS exists for depression. Risk identification depends heavily on clinician index of suspicion rather than a structured instrument — advocacy groups such as Postpartum Support International have specifically pushed for a distinct DSM classification, arguing the current structure also complicates research tracking and, in some payer systems, urgent access to care.

Documentation habits this case reinforces

•     Record the reasoning behind every dose change or medication switch, not only the new order — what symptom prompted it, what was discussed, what was ruled out.

•     Log every portal message touchpoint as part of the clinical record and note when a pattern of contact triggers escalation to an in-person or higher-acuity encounter.

•     Document any attempt (successful or not) to obtain outside records after an ED visit, consult, or inpatient stay — an unanswered records request is still worth charting.

•     Explicitly document a negative screen for safety concerns (self-harm, harm to others, psychosis) at visits where risk is being actively considered — silence in the chart reads, in hindsight, as "never asked."

For the Student or New Grad Reading This

It is tempting, reading a case like this from the outside, to feel certain you'd have caught what apparently got missed. Be careful with that certainty. Every signal described above is far easier to see laid out in a timeline than it is buried inside a fourteen-visit relationship with a sleep-deprived, understandably frustrated patient who is telling you, in good faith, that she just needs a different medication. The lesson isn't that any one clinician failed a test the rest of us would pass. It's that postpartum psychiatric care sits at an intersection of high stakes, high symptom overlap, and fragmented systems — and that building deliberate habits (structured screening, proactive record requests, a lower threshold to escalate refractory insomnia or depersonalization) is how we compensate for the fact that no single visit, message, or lab value will ever tell the whole story on its own.

References

CNN. “Lindsay Clancy repeatedly asked to change medications, psychiatric nurse says.” August 2026.

NBC10 Boston. “Lindsay Clancy trial focuses on medications she was prescribed.” August 2026.

CBS News Boston. “Lindsay Clancy trial focuses on psychiatric care she received before killing children.” August 2026.

ABC News / Good Morning America. “Lindsay Clancy trial: Toxicology expert testifies that drug levels were low.” August 2026.

ABC News. “‘I feel like I’m going to die’: Nurse practitioner testifies about Lindsay Clancy messages.” August 2026.

The Boston Globe. “Nurse practitioner who treated Lindsay Clancy testifies about Duxbury mother’s desperation to improve amid postpartum struggles.” August 2026.

PBS NewsHour. “Lindsay Clancy trial turns focus to medications prescribed before she killed her children.” August 2026.

NPR. “Lindsay Clancy’s trial highlights gaps in understanding, treating postpartum psychosis.” August 2026.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). 2022.

Commonwealth v. Lindsay Clancy. Plymouth Superior Court trial testimony of Rebecca Jollotta, CNP, August 2026.

American College of Obstetricians and Gynecologists (ACOG). Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum, Clinical Practice Guideline. 2023.

This post is for clinical education purposes only and does not constitute legal commentary, medical advice, or a judgment of any individual involved in ongoing litigation. Case facts are drawn from public court reporting and may evolve as the trial continues.